SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (90)1/26/1999 11:45:00 AM
From: Epicenter  Read Replies (2) | Respond to of 3158
 
Dear Peter:

I reviewed SUGN's portfolio recently. I think tyrosine kinase inhibitors are a difficult bunch of targets to get good drugs, in general. I am also not so sure how well the company is run (with famous scientists on the advisory board, sometimes this is a hindrance than a merit--as in the case of ARIAD). For what's its worth, SUGN is pretty low on my list to invest.

Epicenter